Feet on the Ground in St. Petersburg: The Public Mood

by Gilbert Doctorow

One of the first questions put to me by a reader via the Comments function with respect to Monday’s report of my initial impressions after arriving in St Petersburg was: and what is the general mood of people? I begged off answering, saying that I would have to speak to a lot more people before I could confidently answer that question.

Feet on the Ground in St. Petersburg: The Public Mood

Sanctions don’t seem to be effecting the wealthy or the middle class, in Russia, much.

Musk Provides Twitter Censorship Files + State censorship on social networks : the Twitter Files

Musk Provides Twitter Censorship Files

Me.

Biden’s election proved the usefulness of such a tool. The campaign against Musk’s Twitter will thereby likely intensify. So will his effort to fight back.

More popcorn please.

MoA links to an article by Matt Taibbi re: Hunter’s laptop. Matt points the NYT story, Joe Biden, His Son and the Case Against a Ukrainian Oligarch, which claims that Mykola Zlochevsky was the owner of Burisma Holdings. Zlochevsky did not own Burisma, at the time, Ihor Kolomoisky did! In 2012, Burisma changed owners to Privat Group, which was owned by Kolomoisky. On another note, the following video is interesting (despite Elon’s Starlink connection cutting out often). He claims that Twitter will be dedicated to the truth. Let’s see if he continues censoring people (re: Scott Ritter, Garland Nixon, etc). Like MoA asks, please pass the popcorn!

Related:

State censorship on social networks : the Twitter Files

Alzheimer’s latest drug and science journalism’s memory problem

In July, the medical community was rocked by a disappointing reminder of science’s weakest link: the humans doing the work. The journal Science had shared that its six-month investigation supported the findings of whistleblower Matthew Schrag, who first noted altered images in a high-impact paper on Alzheimer’s, published in Nature in 2006. That paper is still flagged on Nature as under review, but the damage has already been done. Alzheimer’s drugs for the last decade and a half have been developed around claims without as much evidence as initially believed—which might also explain why they haven’t been working, leading people to pour false hope into useless and often expensive treatment plans for declining loved ones.

Alzheimer’s latest drug and science journalism’s memory problem